Microvast Reports Third Quarter 2022 Financial Results
“We are pleased with our third quarter performance, delivering year-over-year revenue growth despite continuing difficult market conditions in
“During the quarter, we secured
Results for Q3 2022
Gross profit was
Operating expenses were
Net loss was
Please refer to the tables at the end of this press release for reconciliations of gross profit to non-GAAP adjusted gross profit and net loss to non-GAAP adjusted EBITDA and non-GAAP adjusted net loss.
Results for the Nine Months Ended
Gross profit was
Operating expenses were
Net loss was
Capital expenditures for YTD 2022 were
2022 Outlook
The Company’s backlog at the end of Q3 2022 was
The Company expects capital expenditures for the remainder of FY 2022 to be approximately
Webcast Information
Company management will host a conference call and webcast to discuss the Company’s financial results on
About
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “guidance,” “outlook” or words of similar meaning. These forward-looking statements include, but are not limited to, statements regarding Microvast’s industry and market sizes, future opportunities for
Many factors could cause actual results and the timing of events to differ materially from anticipated results or other expectations expressed in the forward-looking statements, including, among others: (1) risks of operations in the People’s
Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. Readers are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. All information set forth herein speaks only as of the date hereof in the case of information about
Non-GAAP Financial Measures
To provide investors with additional information regarding our financial results,
Reconciliations to the most comparable GAAP measures, gross profit (loss) and net income (loss), are contained in tabular form in the unaudited financial statements below. Non-GAAP adjusted gross profit (loss) is defined as gross profit (loss) excluding non-cash settled share-based compensation expense. Non-GAAP adjusted net loss is defined as net loss excluding changes in fair value of our warrant liability and convertible notes and non-cash settled share-based compensation expense. Non-GAAP adjusted EBITDA is defined as net loss excluding depreciation and amortization, non-cash settled share-based compensation expense, interest expense, interest income, changes in fair value of our warrant liability and convertible notes and income tax expense or benefit.
We use non-GAAP adjusted gross profit (loss), non-GAAP adjusted EBITDA and non-GAAP adjusted net loss for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We consider them to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that these non-GAAP financial measures, when taken together with their most directly comparable GAAP measures, gross profit (loss) and net income (loss), provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results.
We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors.
Non-GAAP financial measures have limitations as an analytical tool, and you should not consider them in isolation, or as a substitute for, financial information prepared in accordance with GAAP. For example, our calculation of non-GAAP adjusted EBITDA may differ from similarly titled non-GAAP measures, if any, reported by our peer companies, or our peer companies may use other measures to calculate their financial performance, and therefore our use of non-GAAP adjusted EBITDA may not be directly comparable to similarly titled measures of other companies. The principal limitation of non-GAAP adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in our financial statements. In addition, it is subject to inherent limitations as it reflects the exercise of judgments by management about which expense and income are excluded or included in determining this non-GAAP financial measure. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. In addition, such financial information is unaudited and does not conform to SEC Regulation S-X and, as a result, such information may be presented differently in our future filings with the
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of |
|||||||
|
|
|
|
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
480,931 |
|
|
$ |
295,816 |
|
Restricted cash, current |
|
55,178 |
|
|
|
83,179 |
|
Accounts receivable (net of allowance for credit losses of |
|
88,717 |
|
|
|
82,707 |
|
Notes receivable |
|
11,144 |
|
|
|
4,505 |
|
Inventories |
|
53,424 |
|
|
|
82,262 |
|
Prepaid expenses and other current assets |
|
17,127 |
|
|
|
19,060 |
|
Amount due from related parties |
|
85 |
|
|
|
— |
|
Total Current Assets |
|
706,606 |
|
|
|
567,529 |
|
Restricted cash, non-current |
|
— |
|
|
|
36,704 |
|
Property, plant and equipment, net |
|
253,057 |
|
|
|
286,346 |
|
Land use rights, net |
|
14,008 |
|
|
|
12,328 |
|
Acquired intangible assets, net |
|
1,882 |
|
|
|
1,696 |
|
Operating lease right-of-use assets |
|
— |
|
|
|
15,509 |
|
Other non-current assets |
|
19,738 |
|
|
|
52,816 |
|
Total Assets |
$ |
995,291 |
|
|
$ |
972,928 |
|
|
|
|
|
||||
Liabilities |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
40,408 |
|
|
$ |
35,972 |
|
Advance from customers |
|
1,526 |
|
|
|
6,589 |
|
Accrued expenses and other current liabilities |
|
58,740 |
|
|
|
79,520 |
|
Income tax payables |
|
666 |
|
|
|
655 |
|
Short-term bank borrowings |
|
13,301 |
|
|
|
7,029 |
|
Notes payable |
|
60,953 |
|
|
|
72,811 |
|
Bonds payable-current |
|
— |
|
|
|
29,259 |
|
Total Current Liabilities |
|
175,594 |
|
|
|
231,835 |
|
Long-term bonds payable |
|
73,147 |
|
|
|
43,888 |
|
Long-term bank borrowings |
|
— |
|
|
|
37,956 |
|
Warrant liability |
|
1,105 |
|
|
|
184 |
|
Share-based compensation liability |
|
18,925 |
|
|
|
115 |
|
Operating lease liabilities |
|
— |
|
|
|
13,530 |
|
Other non-current liabilities |
|
39,822 |
|
|
|
29,564 |
|
Total Liabilities |
$ |
308,593 |
|
|
$ |
357,072 |
|
|
|
|
|
||||
Shareholders’ Equity |
|
|
|
||||
Common Stock (par value of |
$ |
30 |
|
|
$ |
31 |
|
Additional paid-in capital |
|
1,306,034 |
|
|
|
1,398,171 |
|
Statutory reserves |
|
6,032 |
|
|
|
6,032 |
|
Accumulated deficit |
|
(632,099 |
) |
|
|
(757,467 |
) |
Accumulated other comprehensive income/(loss) |
|
6,701 |
|
|
|
(30,911 |
) |
Total Shareholders’ Equity |
|
686,698 |
|
|
|
615,856 |
|
Total Liabilities and Shareholders’ Equity |
$ |
995,291 |
|
|
$ |
972,928 |
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
Revenues |
$ |
36,894 |
|
|
$ |
38,616 |
|
|
$ |
85,204 |
|
|
$ |
139,698 |
|
Cost of revenues |
|
(72,779 |
) |
|
|
(36,623 |
) |
|
|
(129,100 |
) |
|
|
(132,851 |
) |
Gross (loss)/profit |
|
(35,885 |
) |
|
|
1,993 |
|
|
|
(43,896 |
) |
|
|
6,847 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
General and administrative expenses |
|
(57,058 |
) |
|
|
(22,585 |
) |
|
|
(67,810 |
) |
|
|
(83,021 |
) |
Research and development expenses |
|
(13,518 |
) |
|
|
(11,457 |
) |
|
|
(23,199 |
) |
|
|
(33,010 |
) |
Selling and marketing expenses |
|
(7,380 |
) |
|
|
(5,561 |
) |
|
|
(14,242 |
) |
|
|
(17,369 |
) |
Total operating expenses |
|
(77,956 |
) |
|
|
(39,603 |
) |
|
|
(105,251 |
) |
|
|
(133,400 |
) |
Subsidy income |
|
545 |
|
|
|
520 |
|
|
|
2,676 |
|
|
|
1,233 |
|
Loss from operations |
|
(113,296 |
) |
|
|
(37,090 |
) |
|
|
(146,471 |
) |
|
|
(125,320 |
) |
Other income and expenses: |
|
|
|
|
|
|
|
||||||||
Interest income |
|
97 |
|
|
|
870 |
|
|
|
304 |
|
|
|
1,604 |
|
Interest expense |
|
(1,247 |
) |
|
|
(774 |
) |
|
|
(4,630 |
) |
|
|
(2,465 |
) |
Loss on changes in fair value of convertible notes |
|
(3,018 |
) |
|
|
— |
|
|
|
(9,861 |
) |
|
|
— |
|
Gain on changes in fair value of warrant liability |
|
1,113 |
|
|
|
101 |
|
|
|
1,113 |
|
|
|
921 |
|
Other (loss) income, net |
|
(19 |
) |
|
|
349 |
|
|
|
25 |
|
|
|
758 |
|
Loss before provision for income taxes |
|
(116,370 |
) |
|
|
(36,544 |
) |
|
|
(159,520 |
) |
|
|
(124,502 |
) |
Income tax expense |
|
(106 |
) |
|
|
— |
|
|
|
(324 |
) |
|
|
— |
|
Net loss |
$ |
(116,476 |
) |
|
$ |
(36,544 |
) |
|
$ |
(159,844 |
) |
|
$ |
(124,502 |
) |
Less: Accretion of Series C1 Preferred |
|
251 |
|
|
|
— |
|
|
|
2,257 |
|
|
|
— |
|
Less: Accretion of Series C2 Preferred |
|
570 |
|
|
|
— |
|
|
|
5,132 |
|
|
|
— |
|
Less: Accretion of Series D1 Preferred |
|
1,190 |
|
|
|
— |
|
|
|
10,708 |
|
|
|
— |
|
Less: Accretion for noncontrolling interests |
|
1,516 |
|
|
|
— |
|
|
|
9,523 |
|
|
|
— |
|
Net loss attributable to Common Stock shareholders of |
$ |
(120,003 |
) |
|
$ |
(36,544 |
) |
|
$ |
(187,464 |
) |
|
$ |
(124,502 |
) |
Net loss per share attributable to Common Stock shareholders of |
|
|
|
|
|
|
|
||||||||
Basic and diluted |
$ |
(0.49 |
) |
|
$ |
(0.12 |
) |
|
$ |
(1.27 |
) |
|
$ |
(0.41 |
) |
Weighted average shares used in calculating net loss per share of common stock |
|
|
|
|
|
|
|
||||||||
Basic and diluted |
|
243,861,780 |
|
|
|
305,977,372 |
|
|
|
147,836,650 |
|
|
|
301,821,464 |
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of |
|||||||
|
Nine Months Ended
|
||||||
|
|
2021 |
|
|
|
2022 |
|
Cash flows from operating activities |
|
|
|
||||
Net loss |
$ |
(159,844 |
) |
|
$ |
(124,502 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Loss on disposal of property, plant and equipment |
|
6 |
|
|
|
11 |
|
Depreciation of property, plant and equipment |
|
14,398 |
|
|
|
15,161 |
|
Amortization of land use right and intangible assets |
|
499 |
|
|
|
420 |
|
Noncash lease expenses |
|
— |
|
|
|
1,662 |
|
Share-based compensation |
|
58,290 |
|
|
|
72,925 |
|
Changes in fair value of warrant liability |
|
(1,113 |
) |
|
|
(921 |
) |
Changes in fair value of convertible notes |
|
9,861 |
|
|
|
— |
|
Allowance of credit losses |
|
261 |
|
|
|
337 |
|
Provision for obsolete inventories |
|
12,667 |
|
|
|
3,148 |
|
Impairment loss from property, plant and equipment |
|
867 |
|
|
|
1,546 |
|
Product warranty |
|
44,610 |
|
|
|
8,263 |
|
Changes in operating assets and liabilities: |
|
|
|
||||
Notes receivable |
|
10,782 |
|
|
|
1,386 |
|
Accounts receivable |
|
9,425 |
|
|
|
(5,024 |
) |
Inventories |
|
(15,127 |
) |
|
|
(39,517 |
) |
Prepaid expenses and other current assets |
|
(6,874 |
) |
|
|
(3,764 |
) |
Amount due from/to related parties |
|
(128 |
) |
|
|
85 |
|
Operating lease right-of-use assets |
|
— |
|
|
|
(19,284 |
) |
Other non-current assets |
|
52 |
|
|
|
216 |
|
Notes payable |
|
6,868 |
|
|
|
19,942 |
|
Accounts payable |
|
(5,944 |
) |
|
|
(529 |
) |
Advance from customers |
|
(130 |
) |
|
|
5,608 |
|
Accrued expenses and other liabilities |
|
(6,371 |
) |
|
|
(12,203 |
) |
Operating lease liabilities |
|
— |
|
|
|
15,389 |
|
Other non-current liabilities |
|
2,292 |
|
|
|
1,050 |
|
Net cash used in operating activities |
|
(24,653 |
) |
|
|
(58,595 |
) |
|
|
|
|
||||
Cash flows from investing activities |
|
|
|
||||
Purchases of property, plant and equipment |
|
(40,718 |
) |
|
|
(84,722 |
) |
Proceeds on disposal of property, plant and equipment |
|
— |
|
|
|
3 |
|
Net cash used in investing activities |
|
(40,718 |
) |
|
|
(84,719 |
) |
|
|
|
|
||||
Cash flows from financing activities |
|
|
|
||||
Proceeds from borrowings |
|
26,603 |
|
|
|
58,708 |
|
Repayment of bank borrowings |
|
(15,665 |
) |
|
|
(24,482 |
) |
Loans borrowing from related parties |
|
8,426 |
|
|
|
— |
|
Repayment of related party loans |
|
(8,426 |
) |
|
|
— |
|
Merger and |
|
747,791 |
|
|
|
— |
|
Payment for transaction fee in connection with the merger |
|
(42,821 |
) |
|
|
— |
|
Payment to exited noncontrolling interests |
|
(139,038 |
) |
|
|
— |
|
Issuance of convertible notes |
|
57,500 |
|
|
|
— |
|
Net cash generated from financing activities |
|
634,370 |
|
|
|
34,226 |
|
Effect of exchange rate changes |
|
2,314 |
|
|
|
(11,322 |
) |
Decrease in cash, cash equivalents and restricted cash |
|
571,313 |
|
|
|
(120,410 |
) |
Cash, cash equivalents and restricted cash at beginning of the period |
|
41,196 |
|
|
|
536,109 |
|
Cash, cash equivalents and restricted cash at end of the period |
$ |
612,509 |
|
|
$ |
415,699 |
|
|
Nine Months Ended
|
||||||
|
|
2021 |
|
|
2022 |
||
Reconciliation to amounts on consolidated balance sheets |
|
|
|
||||
Cash and cash equivalents |
$ |
572,609 |
|
$ |
295,816 |
||
Restricted cash |
|
39,900 |
|
|
119,883 |
||
Total cash, cash equivalents and restricted cash |
$ |
612,509 |
|
$ |
415,699 |
RECONCILIATION OF GROSS PROFIT (LOSS) TO ADJUSTED GROSS PROFIT (LOSS)
(Unaudited, in thousands of |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
Revenues |
$ |
36,894 |
|
|
$ |
38,616 |
|
|
$ |
85,204 |
|
|
$ |
139,698 |
|
Cost of revenues |
|
(72,779 |
) |
|
|
(36,623 |
) |
|
|
(129,100 |
) |
|
|
(132,851 |
) |
Gross (loss)/profit (GAAP) |
$ |
(35,885 |
) |
|
$ |
1,993 |
|
|
$ |
(43,896 |
) |
|
$ |
6,847 |
|
Gross margin |
|
(97.3 |
) % |
|
|
5.2 |
% |
|
|
(51.5 |
) % |
|
|
4.9 |
% |
|
|
|
|
|
|
|
|
||||||||
Non-cash settled share-based compensation (included in cost of revenues) |
|
2,284 |
|
|
|
1,964 |
|
|
|
2,284 |
|
|
$ |
5,745 |
|
Adjusted gross (loss)/profit (non-GAAP) |
$ |
(33,601 |
) |
|
$ |
3,957 |
|
|
$ |
(41,612 |
) |
|
$ |
12,592 |
|
Adjusted gross margin (non-GAAP) |
|
(91.1 |
) % |
|
|
10.2 |
% |
|
|
(48.8 |
) % |
|
|
9.0 |
% |
RECONCILIATION OF NET LOSS TO ADJUSTED NET LOSS
(Unaudited, in thousands of |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
Net loss (GAAP) |
$ |
(116,476 |
) |
|
$ |
(36,544 |
) |
|
$ |
(159,844 |
) |
|
$ |
(124,502 |
) |
Loss on changes in fair value of convertible notes |
|
3,018 |
|
|
|
— |
|
|
|
9,861 |
|
|
|
— |
|
Gain on changes in fair value of warrant liability |
|
(1,113 |
) |
|
|
(101 |
) |
|
|
(1,113 |
) |
|
|
(921 |
) |
Non-cash settled share-based compensation |
|
49,505 |
|
|
|
19,259 |
|
|
|
49,505 |
|
|
|
64,039 |
|
Adjusted Net Loss (non-GAAP) |
$ |
(65,066 |
) |
|
$ |
(17,386 |
) |
|
$ |
(101,591 |
) |
|
$ |
(61,384 |
) |
RECONCILIATION OF NET LOSS TO EBITDA AND ADJUSTED EBITDA
(Unaudited, in thousands of |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
Net loss (GAAP) |
$ |
(116,476 |
) |
|
$ |
(36,544 |
) |
|
$ |
(159,844 |
) |
|
$ |
(124,502 |
) |
Interest expense, net |
|
1,150 |
|
|
|
(96 |
) |
|
|
4,326 |
|
|
|
861 |
|
Income tax expense |
|
106 |
|
|
|
— |
|
|
|
324 |
|
|
|
— |
|
Depreciation and amortization |
|
5,046 |
|
|
|
4,921 |
|
|
|
14,897 |
|
|
|
15,581 |
|
EBITDA (non-GAAP) |
$ |
(110,174 |
) |
|
$ |
(31,719 |
) |
|
$ |
(140,297 |
) |
|
$ |
(108,060 |
) |
Loss on changes in fair value of convertible notes |
|
3,018 |
|
|
|
— |
|
|
|
9,861 |
|
|
|
— |
|
Gain on changes in fair value of warrant liability |
|
(1,113 |
) |
|
|
(101 |
) |
|
|
(1,113 |
) |
|
|
(921 |
) |
Non-cash settled share-based compensation |
|
49,505 |
|
|
|
19,259 |
|
|
|
49,505 |
|
|
|
64,039 |
|
Adjusted EBITDA (non-GAAP) |
$ |
(58,764 |
) |
|
$ |
(12,561 |
) |
|
$ |
(82,044 |
) |
|
$ |
(44,942 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006008/en/
ir@microvast.com
+1 (212) 871-3927
Source: